



Insulin resistance (IR), a hallmark of various metabolic disorders, represents a diminished responsiveness of target tissues to the actions of insulin, resulting in impaired glucose uptake, dyslipidaemia and endothelial dysfunction.1,2 Worldwide, the prevalence of IR among adults ranges from 15.5% to 46.5%.3–5 The aetiology of IR is multi-factorial, involving a complex interplay of multiple factors. Broadly, genetic predisposition, […]
We often focus on clinical excellence, but spend less time developing broader skills that could help us better lead with purpose and build more fulfilling, impactful careers.
In this episode, part of a mini-series in partnership with LEADderm, Dr Jennifer Soung and Denise Mann explore how clinicians can engage with the media to educate, empower and extend their impact beyond the clinic.
In this interview, Diana Isaacs shares her highlights from the 2026 AACE Annual Meeting, discussing key advances in diabetes management, obesity treatment and diabetes technology, alongside emerging priorities for future endocrinology research and guideline development.
Drawing on the experience of expert faculty and emerging leaders who have already navigated many of the early hurdles when embarking on a career in endocrinology, we asked for one piece of career advice to share with those just starting out. Their reflections highlight the importance of curiosity, compassion, adaptability and purpose in building a fulfilling and sustainable career.
Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our mini-series exploring non-clinical skills that can help you thrive in your clinical career. Today we explore how to develop the right team around you to support your work, and what building that bench can mean for your career, and the life you build alongside it.
Welcome to the summer 2026 issue of touchREVIEWS in Endocrinology. In this issue, we bring together articles that reflect the evolving complexity of endocrine and metabolic disease, while highlighting the growing importance of patient-centred care, translational science and interdisciplinary management. We ...
Pathophysiology of X-linked hypophosphataemia X-linked hypophosphataemia (XLH) is a progressive skeletal disorder, originally defined by Albright in 1937 as hypophosphataemic vitamin D rickets.1 XLH is the commonest form of inherited rickets/osteomalacia and is an X-linked dominant condition.2 The most common ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1RA-based therapies are currently considered to be one of the most attractive classes of medications for managing type 2 diabetes (T2D) because of their impressive weight loss properties, glycated haemoglobin (HbA1c) ...
Omnipod 5 real-world case studies.
Using Omnipod 5 for exercise.
Learn the importance of making an early MASLD/MASH diagnosis, including how to assess for at-risk patients.
Share your knowledge, influence clinical practices and enhance patient care in Endocrinology today!
We often focus on clinical excellence, but spend less time developing broader skills that could help us better lead with purpose and build more fulfilling, impactful careers. In this episode, part of a mini-series in partnership with LEADderm, Dr Jennifer Soung and Denise Mann explore how clinicians can engage with the media to educate, empower and extend their impact beyond the clinic.
Urinary lithogenesis processes are activated in patients with obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D). This is a relatively unfamiliar topic among endocrinologists. Beyond the epidemiological evidence accumulated over the recent years, the purpose of this paper is ...
The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has increased over the past three decades and is estimated to be 30% as of 2022.1 As an indication of disease burden, MASLD-related liver transplantation has already surpassed many other aetiologies as ...
The past century has witnessed substantial evolution in the assessment and management of type 1 diabetes (T1D), paralleling advances in our understanding of the condition and in innovation in technology. Since the ground-breaking discovery of insulin in the 1920s, T1...
The significance of osteoporosis and fragility fractures in individuals with chronic kidney disease (CKD) is becoming increasingly recognized as a major contributor to disability, hospital admissions and mortality. In CKD, bone fragility is worsened by the complex interactions of metabolic ...
Insulin resistance (IR), a hallmark of various metabolic disorders, represents a diminished responsiveness of target tissues to the actions of insulin, resulting in impaired glucose uptake, dyslipidaemia and endothelial dysfunction.1,2 Worldwide, the prevalence of IR among adults ranges from 15.5% to 46.5%.3–5 ...
Highlights Autoantibodies refine autoimmune thyroid disorder diagnosis and risk. Thyroid-stimulating hormone receptor antibody predicts relapse, severity and foetal impact. Thyroid peroxidase antibody and thyroglobulin antibody linked to fertility outcomes. Novel antibodies expand thyroid autoimmunity scope. The interplay between immunology and ...
In this episode, Nicky speaks with Prof. Georgina Ellison-Hughes from King’s College London about the groundbreaking field of senolytics and their potential to advance the treatment of age-related diseases. From understanding the science behind cellular senescence to how senolytic drugs work and what early clinical trials reveal, this episode explores an exciting frontier in longevity medicine.
Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a diverse selection of editorials, reviews and original research articles that highlight both the progress and the ongoing challenges in translating pathophysiological insight into patient-centred care. We begin with ...
The growing convergence of type 2 diabetes (T2D), obesity and dementia represents a pressing public health challenge in ageing populations worldwide.1 Robust epidemiological studies and meta-analyses have consistently shown that T2D is associated with accelerated cognitive decline.1,2 Beyond statistical ...
Gestational diabetes (GD) is a heterogeneous disorder that arises when pancreatic insulin secretion fails to compensate for the insulin resistance of pregnancy. A disbalance in either component, insufficient secretion or excessive resistance, can lead to GD and reflects its variable ...
Fatty liver is the largest liver disease globally and has become a leading cause of liver cirrhosis and end-stage liver disease. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic steatohepatitis (NASH), affects about one-third of the adult population ...
Watch experts discuss the risk assessment and management of heart failure in diabetes, with insights into epidemiology, screening and treatment strategies.
Watch expert speakers discuss recent advances in early autoimmune T1D, with insights into screening and evolving monitoring and management strategies.
Watch multidisciplinary speakers discuss optimising AID outcomes and individualising AID education to support children with type 1 diabetes.
Watch four leading experts discuss how AI is transforming the clinical management of paediatric endocrine disorders including growth hormone disorders.
Watch a leading expert discuss the need for personalised obesity treatment including current evidence for cardiovascular outcomes.
This year, we are celebrating our inaugural touchENDOCRINOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform endocrinology in the years to come.
Selected by our expert Editorial Board and contributing faculty, we are proud to highlight their achievements so far and explore what the future holds for them. We had the pleasure of learning about their unique journeys, career motivations and the inspirations that have shaped their paths. They also shared their perspectives on the most exciting advancements in endocrinology today and their hopes for the future of the field.
Dr Jennifer Snaith is a clinical researcher and endocrinologist who leads the Diabetes in Youth service at St Vincent’s Hospital, Sydney. Her research focuses on the intersection of type 1 diabetes, metabolism and cardiovascular risk. She was awarded the UNSW Dean’s Award for her PhD, which investigated the effects of metformin on muscle and liver insulin resistance in type 1 diabetes using hyperinsulinaemic-euglycaemic clamps.
“It’s a great privilege being a clinician. No two people are the same, and I love working with patients to work out their unique needs.”
Dr Gordon Sloan is a NIHR Clinical Lecturer in Diabetes and Endocrinology at the University of Sheffield (Sheffield, UK) and specializes in diabetic peripheral neuropathy (DPN). DPN, which commonly precedes neuropathic pain and foot ulceration, can severely impact a patient’s quality of life. With a passion for understanding and treating DPN, Dr Sloan has already made a significant impact in the field, having completed a PhD and published original research in renowned journals, including The Lancet.
“Seeing the profound impact diabetic peripheral neuropathy has on people’s lives drives me to improve our understanding and treatment of this condition.”
Dr Kristina Saravinovska is a junior research assistant and PhD candidate at the Faculty of Medicine, University of Belgrade, and an internal medicine resident at the University Clinical Centre of Serbia. She is Co-chair of the European Society of Endocrinology’s (ESE) Young Endocrinologists and Scientists Committee (EYES), where she leads the EYES Observership Programmes and contributes to strategic initiatives through the ESE Clinical Committee, State of Endocrinology Task Force, and EndoCompass project.
“Patients are more than cases—they’re partners in their care, and their experiences continuously drive my research priorities.”
Dr Ignacio Portales-Castillo is a physician-scientist at Washington University School of Medicine in St. Louis, providing nephrology consults at Barnes-Jewish Hospital and researching parathyroid hormone receptor function. He earned his medical degree from the Universidad Autonoma de San Luis Potosi, Mexico, completed his internal medicine residency at Rochester General Hospital, where he received a Clinical Excellence Award, and a nephrology fellowship at Brigham and Women’s Hospital and Massachusetts General Hospital in Boston.
“I learned that every patient holds the potential to inspire new questions, new research, and even a thesis.”
Introducing the Editorial Board of touchREVIEWS in Endocrinology, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of healthcare worldwide.

Diabetes

Director, Diabetes Division and Clinical Research Center of Iatriko P. Falirou Medical Center, Athens, Greece
Dr John Doupis is a former clinical research fellow of the Joslin Diabetes Center, Harvard Medical School, in Boston, MA, USA and scientific partner in Beth Israel Deaconess Foot Center Harvard Medical School, Boston, MA. Currently, he is directing the Diabetes Division and Clinical Research Center of Iatriko P. Falirou Medical Center in Athens, Greece. He has served as a principal investigator in many multicentre phase I, II, III and IV clinical trials, most of which have been published in international journals or presented at congresses. He is a registered reviewer and a member of the editorial board for many major diabetes medical journals. He has given numerous lectures in national and international congresses, presenting over 200 abstracts. His special areas of interest are diabetes and its complications, especially obesity, diabetic neuropathy, diabetic foot, as well as the glucose sensing technologies and insulin pumps. In these fields, he has published more than 50 papers in international medical journals, having more than 1,500 citations.

Diabetes

Professor of Medicine at the Katholieke Universiteit and Chair of Endocrinology at the University Hospital Gasthuisberg Leuven, Belgium
Prof. Chantal Mathieu is a physician-scientist who has contributed to the field of diabetes and endocrinology through basic and clinical research. Her basic research work focuses on pathogenesis and prevention of type 1 diabetes. Prof. Mathieu’s clinical work involving new products and treatment paradigms in diabetes, such as new insulins, adjunct therapies and diagnosis of gestational diabetes have made her a speaker in international fora. Prof. Mathieu coordinates the European clinical trial network for interventions in type 1 diabetes ‘INNODIA’ and the European project ‘EDENT1FI’ on screening for type 1 diabetes. Prof. Mathieu is president of EASD and vice-president of the European Diabetes Forum.

Diabetes

Continuous Glucose Monitoring (CGM) Program Coordinator and Endocrinology Clinical Pharmacy Specialist, Cleveland Clinic Diabetes Center, Cleveland, OH , USA
Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES is the Continuous Glucose Monitoring (CGM) Program Coordinator and Endocrinology Clinical Pharmacy Specialist at the Cleveland Clinic Diabetes Center. She provides medication management and runs a robust CGM shared medical appointment program. Dr Isaacs is a Certified Diabetes Care and Education Specialist and holds board certifications in pharmacotherapy, ambulatory care and advanced diabetes management. She has numerous diabetes publications and research projects with a focus on medications, CGM and diabetes technology.

Diabetes

Emeritus Professor of Medicine and Professor of Nursing, Health and Community Systems at the University of Pittsburgh, PA, USA
Linda Siminerio, RN, PhD is Emeritus Professor of Medicine and Professor of Nursing, Health and Community Systems at the University of Pittsburgh. She has led a career in diabetes research and education. An internationally recognized expert on self-management education and health care delivery models in both pediatric and adult populations, she serves as the Principal Investigator on many studies related to diabetes treatment.
Dr Siminerio has authored numerous publications and served as editor on several diabetes journals. She was President of Health Care and Education, American Diabetes Association and Senior Vice President, International Diabetes Federation (IDF) and Past-Chair of the National Diabetes Education Program (NDEP). In these positions, she has organized and led national and international efforts on the development of programs, standards and care models directed toward health professionals, patients and the community.
Dr Siminerio served as organizing chair for the International Diabetes Federation (IDF) World Diabetes Congress and IDF translation research program, Building Research in Diabetes Global Environments and Systems (BRIDGES).
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.